Stocks Health care MSLE
NASDAQ · Health careSatellos Bioscience Inc. (MSLE)
It posted a net loss of $24.9M. In fiscal 2025 capital spending exceeded operating cash flow by $23.6M. At December 31, 2025 it held $9.8M in cash. Its latest periodic report to the SEC is the annual report (Canadian issuer) (40-F) filed on March 27, 2026.
Key facts about Satellos Bioscience Inc.
- Net worth
- Satellos Bioscience Inc. has a market value (market cap) of $158.7M at the latest share price, and shareholders' equity of $27.8M on its balance sheet at December 31, 2025. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used $23.6M of cash.
- Latest report
- The latest periodic report (annual report (Canadian issuer), 40-F) was filed with the SEC on March 27, 2026 and covers the period to December 31, 2025. Open on SEC EDGAR
What Satellos Bioscience Inc. does
Satellos Bioscience Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker MSLE.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$24.9M | -$1.70 | -$23.6M |
| 2025 | n/a | -$20.6M | -$2.16 | -$18.3M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Satellos Bioscience Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 6, 2026
- November 5, 2026
- October 27, 2026
- October 21, 2026
- October 5, 2026
- September 30, 2026
- September 24, 2026
- September 15, 2026
- September 9, 2026
- September 1, 2026
Insider trades
What the people running Satellos Bioscience Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
Who owns MSLE
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Qiming U.S. Healthcare Fund III, L.P.13G, passive with 3 related filers | 8.3% | May 12, 2026 |
| Brian Matthew Bloom13G, passive with 2 related filers | 7.35% | May 15, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 26 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Franklin Resources Inc | 938,666 | 0 |
| Siren, L.L.C. | 892,074 | 0 |
| Vivo Capital, LLC | 813,666 | 0 |
| Point72 Asset Management, L.P. | 682,700 | -8,078 |
| Sphera Funds Management Ltd. | 652,590 | +163,383 |
| Woodline Partners LP | 500,432 | 0 |
| Stonepine Capital Management, LLC | 491,624 | +391,624 |
| Montanova Capital, LLC | 475,000 | 0 |
| Avidity Partners Management LP | 387,769 | -387,769 |
| Saturn V Capital Management LP | 350,000 | 0 |
| Soleus Capital Management, L.P. | 314,359 | -100,000 |
| 683 Capital Management, LLC | 230,833 | 0 |
| ADAR1 Capital Management, LLC | 222,555 | 0 |
| AWM Investment Company, Inc. | 180,000 | new |
| Millennium Management LLC | 152,768 | -145,665 |
| Adage Capital Partners GP, L.L.C. | 150,000 | -230,354 |
| Empery Asset Management, LP | 107,100 | -123,000 |
| Citadel Advisors LLC | 67,738 | +25,246 |
| Morgan Stanley | 25,732 | +4,549 |
| China Universal Asset Management Co., Ltd. | 20,000 | +13,600 |
Insiders
Questions about MSLE
What does Satellos Bioscience Inc. do?
Satellos Bioscience Inc. is a company in the Health care sector, listed on NASDAQ as MSLE. Its shares trade on NASDAQ under the ticker MSLE.
What is Satellos Bioscience Inc.'s net worth?
Satellos Bioscience Inc. has a market value (market cap) of $158.7M at the latest share price, and shareholders' equity of $27.8M on its balance sheet at December 31, 2025. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Satellos Bioscience Inc. profitable?
No. In fiscal 2025 it reported a net loss of $24.9M.
When did Satellos Bioscience Inc. last report?
Its most recent periodic report is the annual report (Canadian issuer) (40-F) filed on March 27, 2026. It covers the period to December 31, 2025. Its newest filing of any kind is the foreign issuer update from November 6, 2026.
Similar companies
Compare MSLE with
Follow MSLE
Get an email when Satellos Bioscience Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Satellos Bioscience Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.